Inspection Readiness Starts Before Enrollment: What FDA’s New GCP Warning Means for Trial Operations

FDA’s message is about evidence, not geography alone

FDA stated that Good Clinical Practice applies regardless of whether a trial is conducted in a major academic center, a community clinic, a CRO-managed research unit, or a site outside the United States. The agency’s central concern is whether participant protections were maintained and whether submitted data can be independently validated. FDA specifically identified access to source data and consent documentation as necessary components of that validation. ([fda.gov](https://www.fda.gov/news-events/fda-voices/good-clinical-practices-are-not-optional-fdas-commitment-human-subject-protections-and-gold-standard))

This distinction matters. A domestic address does not make data inherently reliable, just as a foreign address does not make it unreliable. What matters operationally is whether the investigator and sponsor can demonstrate how the study was conducted, who performed each task, which records were used to support eligibility and endpoints, how changes were controlled, and whether the available evidence agrees across systems.

FDA’s BIMO program uses on-site inspections, data audits, and remote regulatory assessments to evaluate regulated research. The program covers clinical investigators, sponsors, CROs, IRBs, bioequivalence facilities, and other regulated parties. FDA reports that the broader program conducts more than 1,000 inspections annually, domestically and internationally. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information/bioresearch-monitoring-program-information?utm_source=openai))

Inspectability should be tested during feasibility

Traditional feasibility questionnaires devote substantial attention to patient counts, competing studies, equipment, staffing, and enrollment projections. Those questions are necessary, but they do not establish whether the site’s data environment will withstand detailed review.

Sponsors and CROs should add an inspectability assessment before final site selection. This does not require a full audit. It requires a practical review of how protocol-critical information will move through the site. If eligibility depends on records from a hospital, specialist, imaging center, local laboratory, pharmacy, wearable device, or electronic health record, the study team should determine how those records will be obtained, verified, retained, and produced for monitoring or inspection.

This is particularly important in community research. Participants may receive care across several unaffiliated providers. In South Florida or Puerto Rico, records may also exist in English and Spanish, use different date or measurement conventions, or be stored in systems with different release procedures. Those realities can be managed, but only if they are identified before the first screening visit.

• Can the site obtain the records required to confirm eligibility within the protocol’s screening window?
• Who owns each original record, and will the site retain an adequate copy when direct access is unavailable?
• Can the investigator access data created by affiliated clinics, local laboratories, pharmacies, or mobile providers?
• What happens to study data if a vendor relationship ends or a staff member’s account is disabled?
• Are translated records, consent materials, and interpreter involvement documented consistently?

Create a source and system map before first participant in

A source data agreement is useful only when it reflects the study’s actual workflow. Generic language such as “electronic medical record and site worksheets” is rarely enough for a complex protocol. The study team should map each critical-to-quality data element to the place where it is first recorded.

ICH E6(R3), finalized by FDA in September 2025, emphasizes quality by design, proportionality, clear responsibilities, and reliable trial results. It also calls for the sponsor and investigator or institution to maintain a record of where essential records, including source records, are located. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp?utm_source=openai))

For a metabolic study, for example, weight may originate from a calibrated site scale, an outside clinic note, or a connected device. A gastrointestinal endpoint might begin in a participant diary before appearing in an electronic data capture system. Vaccine temperature data may be generated automatically by a monitoring platform. Each workflow creates different questions about access, attribution, corrections, review, and retention.

• Data element and protocol purpose
• Original source and any certified-copy process
• System owner and responsible staff role
• Expected timing of entry and investigator review
• Method for documenting corrections or late entries
• Location of metadata and audit trails
• Retention and export plan at study closeout

Electronic access must survive staff turnover and study closeout

Electronic systems often make trial conduct more efficient while making record ownership less obvious. Sites may use sponsor portals, eConsent platforms, electronic diaries, laboratory portals, imaging systems, temperature-monitoring tools, electronic regulatory binders, and internal clinical systems in a single study.

FDA’s guidance on electronic records says regulated entities should preserve the authenticity, integrity, confidentiality, meaning, and associated metadata of electronic records. Records must remain available for inspection for the applicable retention period, with adequate backup and recovery controls. ([fda.gov](https://www.fda.gov/media/166215/download?utm_source=openai))

A common operational weakness is access built around one coordinator’s individual account. When that employee leaves, the site discovers that reports cannot be regenerated, audit trails are unavailable, or records can be viewed but not exported. Another weakness appears at closeout, when access to a sponsor or vendor platform ends before the site confirms that all required records have been retained.

Sites should maintain a current system inventory, assign a primary and backup administrator where permitted, and test record retrieval periodically. Sponsors should also specify which records the site must retain and how those records will be provided when the sponsor controls the platform.

Consent reconstruction deserves its own quality review

FDA’s recent statement gives particular attention to whether informed consent was freely given and documented. A signed form is important, but it does not by itself reconstruct the consent process. Inspectors may need to determine which version was used, whether consent occurred before study procedures, who conducted the discussion, whether the participant had questions, and whether translated materials or an interpreter were involved.

For sites serving multilingual communities, language access cannot be handled as an improvised accommodation after a participant arrives. The site should know which translated documents have IRB approval, when a short-form process is permitted, how interpreter participation is documented, and how translated updates will be managed when reconsent is required.

A targeted consent review should compare the signed document, consent note, visit timeline, IRB approval history, screening procedures, delegation records, and electronic timestamps. Any discrepancy should be investigated promptly rather than left for monitor discovery months later.

Run a reconstruction drill, not another binder review

Many inspection-readiness exercises focus on whether expected documents are filed. That is useful, but it does not test whether the evidence works together. A stronger exercise selects one participant and one critical endpoint, then reconstructs the story across every relevant record.

The reviewer should be able to follow the participant from consent through eligibility, randomization or treatment, investigational product accountability, safety reporting, endpoint assessment, data entry, queries, and investigator oversight. Dates, staff identities, measurements, and clinical decisions should agree or have documented explanations.

Sites can run a small reconstruction drill after the first enrolled participant, following major staff or system changes, and periodically during enrollment. Sponsors and CROs can use the results to adjust monitoring and training. The objective is not to create perfect-looking files. It is to identify conditions that could prevent an independent reviewer from understanding what actually happened.

• Select a participant with enough activity to test the workflow.
• Pull records without relying on the coordinator who created them.
• Compare source, EDC, laboratory, pharmacy, safety, and vendor data.
• Confirm that corrections preserve the original entry and include a reason where appropriate.
• Document gaps, assign owners, and evaluate whether the issue could affect other participants.

The practical standard: credible, accessible, and explainable

FDA’s September announcement does not create a new site checklist. It reinforces a longstanding standard with a sharper enforcement signal: clinical evidence must be ethically obtained, credible, and available for validation.

For sponsors, that means inspectability should influence country strategy, vendor qualification, protocol design, site selection, and oversight. For CROs, it means monitoring plans must evaluate the systems and processes behind critical data, not simply confirm that fields were entered. For investigators and sites, it means maintaining control of records and oversight even when tasks and technology are distributed.

The most useful question is not, “Would the binder pass an inspection?” It is, “Could an independent reviewer reconstruct the participant’s experience and the data used in the analysis without depending on memory?” If the answer is uncertain, the time to fix the workflow is while the trial is active.